Protalix BioTherapeutics (PLX) Return on Capital Employed (2011 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Return on Capital Employed of 30.47% for Q1 2026, up 2109.0% year-over-year from 1.38% in Q1 2025, and up 409.06% quarter-over-quarter from 9.86% in Q4 2025.
Protalix BioTherapeutics (PLX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Protalix BioTherapeutics' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 30.47% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2109.0% year-over-year to 30.47%; the TTM figure through Mar 2026 stood at 30.47% (up 2109.0% YoY), while the FY2025 annual figure was 10.71%, down 1806.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 30.47%, up from 9.86% in the prior quarter.
- The five-year high for Return on Capital Employed was 30.47% in Q1 2026, with the low at 66.57% in Q3 2022.
- The 5-year median for Return on Capital Employed is 9.36% (2024), against an average of 9.19%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed jumped 9700 bps in 2023, then slumped 6790 bps in 2024.
- Protalix BioTherapeutics' Return on Capital Employed stood at 54.64% in 2022, then surged by 147 bps to 25.85% in 2023, then tumbled by 64 bps to 9.36% in 2024, then plunged by 205 bps to 9.86% in 2025, then soared by 409 bps to 30.47% in 2026.
- Business Quant data shows PLX's Return on Capital Employed at 30.47% in Q1 2026, 9.86% in Q4 2025, and 10.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 7.88% |
| 10 | Protalix BioTherapeutics | 191.57 Mn | 150.91 Mn | 12.13 Mn | 31.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.08% |
| Mar 31, 2026 | 30.47% |
| Dec 31, 2025 | -9.86% |
| Sep 30, 2025 | 10.90% |
| Jun 30, 2025 | 15.79% |
| Mar 31, 2025 | 9.38% |
| Dec 31, 2024 | 9.36% |
| Sep 30, 2024 | -17.02% |
| Jun 30, 2024 | -45.20% |
| Mar 31, 2024 | 24.96% |
| Dec 31, 2023 | 25.85% |
| Sep 30, 2023 | 30.43% |
| Jun 30, 2023 | 22.70% |
| Mar 31, 2023 | -45.87% |
| Dec 31, 2022 | -54.64% |
| Sep 30, 2022 | -66.57% |
| Jun 30, 2022 | -44.66% |
| Mar 31, 2022 | -52.18% |
| Dec 31, 2021 | -45.07% |
| Sep 30, 2021 | -22.45% |